Pipeline and Partnering
We forge deep, collaborative alliances and partnerships across multiple domains. Our unique network of academic partners allows us to access cross-therapeutic expertise and unprecedented proprietary databases in genomic medicine R&D. Furthermore, our innovative platform and flexible business model enable the delivery of robust non-clinical candidates.
Pipeline
Redefine the Scope of Possibilities in Genomic Medicine
Leveraging our expertise in computational biology, we extend our pipeline into bioproduction optimization, specializing in both viral and non-viral delivery systems.
Gene & RNA-based therapies
Target Receptors Identification & Viral Vector Design
- Tech R&D
- In Silico Design
- Wet Lab Validation
- CNSCNS: 77%
- OphthalmologyOphthalmology: 56%
- Rare diseaseRare disease: 56%
- OncologyOncology: 56%
Non Viral Vector Design
- Tech R&D
- In Silico Design
- Wet Lab Validation
- OncologyOncology: 77%
Payload design
- Tech R&D
- In Silico Design
- Wet Lab Validation
- OncologyOncology: 56%
Bioproduction
Bioproduction optimization
- Tech R&D
- In Silico Design
- Wet Lab Validation
- 2 programs (AAV, LV)2 programs (AAV, LV): 80%
Cell Therapy
Cell Therapy Pipeline
- Tech R&D
- In Silico Design
- Wet Lab Validation
- CAR designCAR design: 40%
- Viral vectorsViral vectors: 40%
Partnering
Igniting discoveries through collaborative partnerships
By forging deep, collaborative alliances, we develop co-partnerships with our clients that spark innovation and will achieve breakthroughs in genomic medicine.
Our partnerships merge tailored innovation with unmatched adaptability, driving breakthroughs in genomic medicine that accelerate drug development while minimizing risks. Our co-development business model centers on strategic collaboration with academic and industrial partners that drive mutual growth and innovation. This allows us to leverage the strengths of our partners while ensuring mutual benefit.
